Iovance Biotherapeutics, Inc. Overview
Pro stress-test →Iovance Biotherapeutics is a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication, marking a major breakthrough in oncology.
Strategic Profile
Pro stress-test →The company delivered approximately 30 percent quarterly revenue growth in Q4 2025, with growth driven by increasing demand for Amtagvi. After ongoing improvements in operations and gross margin, Iovance is well positioned for future profitability. The company achieved 50% gross margin and $303M cash fund Iovance to Q3 2027.
Competitive Landscape
Pro stress-test →Iovance has 40 competitors including Replimune, competing in the immuno-oncology and cell therapy space. The company's advantage stems from being first-to-market with an FDA-approved T cell therapy for solid tumors, though competitors in CAR-T and next-generation TIL therapies pose long-term challenges.
Industry Context
Iovance Biotherapeutics, Inc. operates in Biopharmaceuticals - Immuno-Oncology & Cell Therapy.
Key facts
Founded: 2007 · Headquarters: San Carlos, California · Employees: 838 · Revenue: $264M (FY2025) · Market cap: $1.02B